My understanding is that a second matter remains to be heard - relates to an action launched in June last year. So might pay to contain the enthusiasm for the time being ...
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
